Iv Busulfan Administered Q12 Vs Q6 Hrs During Conditioning of Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Has Comparable Pharmacokinetics and Significant Reduction in Nursing/Pharmacist Costs
Year: 2011
Type: article
Abstract: Inaccurate busulfan dosing during AlloSCT conditioning can result in graft failure or regimen-related toxicity (Andersson, BBMT, 2009). IV busulfan divided q6hrs is safe and effective in pediatric AlloSCT recipients at a dose of 4 mg/kg/day in patients ≤ 4 yrs old and at a dose of 3.2 mg/kg/day in patients > 4 yrs old (Wall et al, PBC, 2010). Less frequent dosing regimens are attractive for the possibility of cost-effectiveness, but data is limited on comparing q12 to q6hr infusions of IV busulfan in pediatric AlloSCT recipients.
Institutions: Columbia University, University of Pennsylvania
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2037896960